登录 | 注册    关注公众号  
微信公众号
搜索
 > 【TREM2】

TREM2信息

英文名称:Triggering receptor expressed on myeloid cells 2
中文名称:触发在骨髓细胞上2表达的受体
靶点别称:TREM-2,Triggering receptor expressed on monocytes 2,PLOSL2,Trem2b,Trem2a,Trem2c,Triggering Receptor Expressed On Myeloid Cells 2a
上市药物数量:0
临床药物数量:4
最高研发阶段:临床二期

TREM2分子别名

Triggering receptor expressed on myeloid cells 2,TREM2,TREM-2

TREM2分子背景

Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell surface receptor of the immunoglobulin superfamily. The TREM2 is found in various tissue macrophages, such as CNS microglia, bone osteoclasts, alveolar, peritoneal and intestinal macrophages. TREM2 is also present on cultured bone marrow-derived macrophages and monocyte-derived dendritic cells. Some research have identified a rare variant of TREM2 that is a risk factor for Alzheimer disease (AD), which is the most common form of late-onset dementia.The extracellular region of TREM2 contains a single immunoglobulin superfamily domain and binds polyanionic ligands, such as bacterial lipopolysaccharide (LPS) and phospholipids8. Upon ligand binding, TREM2 transmits intracellular signals through an adaptor, DAP12 (also known as TYRO protein tyrosine kinase-binding protein (TYROBP)), which is associated with the transmembrane region of TREM2 and which recruits the protein tyrosine kinase SYK through its cytosolic immunoreceptor tyrosine-based activation motifs (ITAMs). TREM2 is a pro-tumorigenic marker of tumor-infiltrating macrophages in mouse models and human tumors that can be targeted to curb tumor growth and improve the efficacy of checkpoint blockade therapy while remodeling the landscape of tumor-infiltrating macrophages.

TREM2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定